These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 9409292)
1. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood. Orvim U; Barstad RM; Orning L; Petersen LB; Ezban M; Hedner U; Sakariassen KS Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3049-56. PubMed ID: 9409292 [TBL] [Abstract][Full Text] [Related]
2. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. Orvim U; Barstad RM; Vlasuk GP; Sakariassen KS Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2188-94. PubMed ID: 7489241 [TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Lev EI; Marmur JD; Zdravkovic M; Osende JI; Robbins J; Delfin JA; Richard M; Erhardtsen E; Thomsen MS; Lincoff AM; Badimon JJ Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):1036-41. PubMed ID: 12067917 [TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation. Li R; Panckeri KA; Fogarty PF; Cuker A; Diamond SL Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Bossavy JP; Sakariassen KS; Rübsamen K; Thalamas C; Boneu B; Cadroy Y Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1348-53. PubMed ID: 10323789 [TBL] [Abstract][Full Text] [Related]
8. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis]. Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470 [TBL] [Abstract][Full Text] [Related]
10. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Kirchhofer D; Tschopp TB; Baumgartner HR Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1098-106. PubMed ID: 7627702 [TBL] [Abstract][Full Text] [Related]
11. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide Arg-Gly-Asp-Val. Experiments with flowing non-anticoagulated human blood. Salatti JA; Anton P; Nemerson Y; Sakariassen KS Blood Coagul Fibrinolysis; 1993 Dec; 4(6):881-90. PubMed ID: 8148480 [TBL] [Abstract][Full Text] [Related]
13. Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition. Li R; Panckeri KA; Fogarty PF; Diamond SL Haemophilia; 2015 Mar; 21(2):266-274. PubMed ID: 25311576 [TBL] [Abstract][Full Text] [Related]
14. Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin. Colace TV; Muthard RW; Diamond SL Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1466-76. PubMed ID: 22516070 [TBL] [Abstract][Full Text] [Related]
15. alpha-thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood. Salatti JA; Fenton J; Anton P; Sakariassen KS Blood Coagul Fibrinolysis; 1994 Aug; 5(4):561-6. PubMed ID: 7841312 [TBL] [Abstract][Full Text] [Related]
16. Functional characterization of tissue factor in von Willebrand factor-dependent thrombus formation under whole blood flow conditions. Matsunari Y; Sugimoto M; Doi M; Matsui H; Kawaguchi M Int J Hematol; 2016 Dec; 104(6):661-668. PubMed ID: 27562418 [TBL] [Abstract][Full Text] [Related]
17. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343 [TBL] [Abstract][Full Text] [Related]
19. A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation. Orning L; Fischer PM; Hu CK; Agner E; Engebretsen M; Husbyn M; Petersen LB; Orvim U; Llinas M; Sakariassen KS Thromb Haemost; 2002 Jan; 87(1):13-21. PubMed ID: 11848442 [TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Golino P; Ragni M; Cirillo P; D'Andrea D; Scognamiglio A; Ravera A; Buono C; Ezban M; Corcione N; Vigorito F; Condorelli M; Chiariello M Circ Res; 1998 Jan 9-23; 82(1):39-46. PubMed ID: 9440703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]